AK117/Placebo with Azacitidine
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 90 patients (estimated)
- Sponsors
- Akeso
- Tags
- Monoclonal Antibody, CD47, Closed Label (Masked), Placebo, Randomization
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1855
- NCT Identifier
- NCT06196203
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.